All patients
Age < 65y (younger) Age > 75y (older) ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% smoker (current or former)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
squamous cell - mNSCLC - L2, immune chekpoint inhibitors vs. non platinum-based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 017, 2015 0.59 [0.44; 0.79]
0.59 [0.44 ; 0.79 ] CheckMate 017, 2015 1 0% 272 NA not evaluable deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
0.31 [0.14 ; 0.69 ] CheckMate 017, 2015 1 0% 272 NA not evaluable PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
0.48 [0.24 ; 0.96 ] CheckMate 017, 2015 1 0% 272 NA not evaluable progression or deaths (PFS)detailed results CheckMate 017, 2015 0.62 [0.47; 0.81]
0.62 [0.47 ; 0.81 ] CheckMate 017, 2015 1 0% 272 NA not evaluable objective responses (ORR)detailed results CheckMate 017, 2015 2.60 [1.26; 5.35]
2.60 [1.26 ; 5.35 ] CheckMate 017, 2015 1 0% 272 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
0.53 [0.19 ; 1.48 ] CheckMate 017, 2015 1 0% 272 NA not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
0.10 [0.03 ; 0.33 ] CheckMate 017, 2015 1 0% 260 NA not evaluable STRAE (any grade)detailed results CheckMate 017, 2015 0.23 [0.11; 0.51]
0.23 [0.11 ; 0.51 ] CheckMate 017, 2015 1 0% 260 NA not evaluable TRAE (any grade)detailed results CheckMate 017, 2015 0.22 [0.12; 0.41]
0.22 [0.12 ; 0.41 ] CheckMate 017, 2015 1 0% 260 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.06 [0.03; 0.13]
0.06 [0.03 ; 0.13 ] CheckMate 017, 2015 1 0% 260 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
0.16 [0.01 ; 3.24 ] CheckMate 017, 2015 1 0% 260 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 017, 2015 0.28 [0.09; 0.89]
0.28 [0.09 ; 0.89 ] CheckMate 017, 2015 1 0% 260 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
0.23 [0.05 ; 1.13 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.12 [0.01; 2.29]
0.12 [0.01 ; 2.29 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.01; 1.76]
0.10 [0.01 ; 1.76 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.06; 15.91]
0.98 [0.06 ; 15.91 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
0.16 [0.01 ; 3.24 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.09 [0.01; 0.73]
0.09 [0.01 ; 0.73 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.03 [0.00; 0.58]
0.03 [0.00 ; 0.58 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.19 [0.02; 1.66]
0.19 [0.02 ; 1.66 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
0.24 [0.01 ; 5.45 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results Out of scale CheckMate 017, 2015 0.01 [0.00; 0.15]
0.01 [0.00 ; 0.15 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
0.16 [0.01 ; 3.24 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 017, 2015 1.98 [0.07; 59.45]
1.98 [0.07 ; 59.45 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
0.24 [0.01 ; 5.45 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 00:14 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 280,168,169
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743